Inxight Drugs

U.S. Department of Health & Human Services Divider Arrow

National Institutes of Health Divider Arrow

NCATS

This repository is under review for potential modification in compliance with Administration directives.

Return Home Inxight Drugs

Home
Browse Drugs
Search
- Structure Search
- Sequence Search
Downloads
About

Show Filters

Hide Filters

Development Status

Other

166

Possibly Marketed Outside US

32

Investigational

7

US Previously Marketed

4

US Approved Rx

3

All Match

Any Match

Exclude Selected

Exclude Selected

Primary Target

Cyclooxygenase-2

2

Oxidative Stress

2

Apoptosis

1

Brain-derived neurotrophic factor

1

Carboxylesterase 2

1

All Match

Any Match

Exclude Selected

Exclude Selected

Highest Phase

Approved

9

Not Provided

1

Phase I

1

All Match

Any Match

Exclude Selected

Exclude Selected

Approval Year

Unknown

176

1995

4

2017

4

2013

3

1921

2

All Match

Any Match

Exclude Selected

Exclude Selected

Condition

Unknown

3

Acne

2

Alcohol abuse

1

Alzheimer’s disease

1

Blood Transfusion

1

All Match

Any Match

Exclude Selected

Exclude Selected

Treatment Modality

Primary

12

Inactive ingredient

3

Palliative

2

Curative

1

Diagnostic

1

All Match

Any Match

Exclude Selected

Exclude Selected

CNS Activity

CNS Active

4

CNS Non-penetrant

2

All Match

Any Match

Exclude Selected

Exclude Selected

Originator

Bamberger, E.

1

C. M. Industries S. A.

1

CJSC LEKKO Pharmaceuticals

1

Cahours, A.A.T.

1

Duke University Medical Center

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Class

Chemical

204

Mixture

10

All Match

Any Match

Exclude Selected

Exclude Selected

Code System

FDA UNII

214

CAS

213

EPA CompTox

209

PUBCHEM

205

ECHA (EC/EINECS)

137

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 1

BLOOD AND BLOOD FORMING ORGANS

1

NERVOUS SYSTEM

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 2

ANTITHROMBOTIC AGENTS

1

PSYCHOLEPTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 3

ANTITHROMBOTIC AGENTS

1

ANXIOLYTICS

1

All Match

Any Match

Exclude Selected

Exclude Selected

ATC Level 4

Benzodiazepine derivatives

1

Vitamin K antagonists

1

All Match

Any Match

Exclude Selected

Exclude Selected

Substance Form

Principal Form

203

Salts, Hydrates, Esters, etc.

11

All Match

Any Match

Exclude Selected

Exclude Selected

Search results for telotristat root_codes_code in Code Literal (approximate match)

Showing 211 - 214 of 214 results

First page
Previous page
22
Next page disabled
Next page disabled

ETHYL 3-HEXENOATE, (3Z)-

R35DY1229O

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

SODIUM ETHYLXANTHATE

3R5A3652VK

Export Data
Search for Structure

Status:

Other

Class (Stereo):

CHEMICAL (ACHIRAL)

ETHYL PYRUVATE

03O98E01OB

Export Data
Search for Structure

Status:

Possibly Marketed Outside US

First approved in 1987

Class (Stereo):

CHEMICAL (ACHIRAL)

Targets:

Oxidative Stress

Conditions:

Blood Transfusion

Coronary Disease

CTI-01 (ethyl pyruvate) is an investigational anti-inflammatory agent for the treatment of critical inflammatory conditions. CTI-01 was developed by Critical Therapeutics as a stable prodrug of pyruvate, a potent antioxidant, and a free radical scave...

nger. The drug showed an anti-inflammatory and tissue protection activity in animal models of pancreatitis, ischemia-reperfusion injury, sepsis, renal injury, and endotoxemia. CTI-01 was investigated in phase 2 clinical trials on patients undergoing cardiac surgery with cardiopulmonary bypass, but despite positive results in animal models, administration of EP does not appear to confer any benefit to cardiac surgical patients undergoing cardiopulmonary bypass. Besides clinical applications, ethyl pyruvate is long used as an additive to pharmaceutical preparations and foods, including candy, beverages, and baked goods. It is generally recognized as safe by the FDA.

OMEGA-3-ACID ETHYL ESTERS

D87YGH4Z0Q

Status:

US Approved Rx (2020)

First approved in 1997

Class:

MIXTURE

Showing 211 - 214 of 214 results

First page
Previous page
22
Next page disabled
Next page disabled

HHS VULNERABILITY DISCLOSURE

For language access assistance, contact the NCATS Public Information Officer

National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966


			version 1.1